Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Dr David Stamler Biotech Showcase Presentation

January 8, 2018August 16, 2022 Alterity Therapeutics

Prana Biotechnology JPM investor presentation_updated

2018

Post navigation

Prana meeting with investors at world’s largest healthcare conference in San Francisco

PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Related Posts

Prana Completes Recruitment in Alzheimer’s Trial

July 17, 2013August 16, 2022

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019August 16, 2022

Prana Completes Recruitment in Huntington Trial

July 17, 2013August 16, 2022

Recent Posts

Appendix 4C – Q2 FY23 Quarterly Cash Flow Report
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
Alterity Therapeutics to Participate in the Sachs Associates 6^th Annual Neuroscience Innovation Forum

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065